A team from Thermo Fisher will co-locate with AstraZeneca scientists to work on collaborative R&D projects with a focus initially on chromatography, molecular genomics and proteomics.

“When two global life science leaders join forces in an open innovation environment, truly exceptional conditions for breakthrough discovery and progress are created. Welcoming Thermo Fisher Scientific into BioVentureHub at AstraZeneca’s strategic R&D campus in Gothenburg – adjacent to GoCo Health Innovation City – marks a significant step and unlocks dynamic opportunities for open scientific co-creation between AstraZeneca and Thermo Fisher Scientific,” says Magnus Björsne, CEO, AstraZeneca BioVentureHub.

A growing innovation ecosystem

The AstraZeneca BioVentureHub is part of a growing innovation ecosystem in Gothenburg that includes the GoCo Health Innovation City, future home of Thermo Fisher’s bioanalytical laboratory that is under construction and expected to begin operations in March 2026.

“This is a unique opportunity to co-locate with AstraZeneca scientists, driving collaborative innovation, strengthening the science ecosystem and driving value generation for all collaborators, giving easy access to cutting edge technologies for emerging life sciences and biotech companies as well as academic groups,” says Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific.